12-26-0

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

							x Patent Application				
I	P P	nitte	d har	owith for f	iling under 35		shington, D.C. 20231	3/h) is a new utility natent an	unlication for an		
Ī	smitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:										
	COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS										
	SAID COMPOUNDS AND ME I HODS FOR IDENTIFYING SAID COMPOUNDS										
									or and a		
	and inv	200 E									
		Joachim Hauber Alexander Thorsten Prechtel									
l											
	If a Ci	ONT	ΝΙΙΔ	TION AP	PLICATION.	check appro	poriate box and suppl	y the requisite information:			
					•		,	of prior application No.:			
	Which							-			
		onti	nuat	ion 🛚	Divisional	☐ Conti	nuation-in-part (CIP)	of prior application No.:			
	Which	is a	: .								
		onti	nuat	ion 🛚	Divisional	☐ Conti	nuation-in-part (CIP)	of prior application No.:			
	Enclo	sed a	are:			Δn	plication Elements				
						-					
	1.	X	Filin	ig fee as c	alculated and	d transmitted	as described below				
	2.	X	Spe	cification	having	100	pages and	including the following:			
		a.	X	Descripti	ve Title of the	e Invention					
		b.		Cross Re	eferences to	Related App	lications (if applicable	e)			
I		c. Statement Regarding Federally-sponsored Research/Development (if applicable)									
		d. Reference to Microfiche Appendix (if applicable)									
		e.	X	Backgro	und of the Inv	ention					
	f. 🗵 Brief Summary of the Invention										
		g.	X	Brief Des	scription of th	e Drawings	(if drawings filed)				
		h.	X	Detailed	Description						
		i.	X	Claim(s)	as Classified	i Below					
		j. 🗵 Abstract of the Disclosure									
- #											

P01ULRG/REV05

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

4

				Application E	iements ((Continued)	
3.	X	Dra	wing(s) <i>(when neces</i>	sary as prescribed	by 35 US	C 113)	
	a.	X	Formal	Number of Sheets		15	
	b.		Informal	Number of Sheets			
4.		Oat	h or Declaration				
	a.		Newly executed (or	iginal or copy)	☐ Une	executed	
	b.		Copy from a prior a	pplication (37 CFR	1.63(d)) <i>(t</i>	for continuation	divisional application only)
	C.		With Power of Attor	ney 🗆 Witho	ut Power	of Attorney	
	d.		DELETION OF INV Signed statement a see 37 C.F.R. 1.63(ttached deleting inv	rentor(s) n	amed in the p	rior application,
5.		The Box		the prior application as being part of th	, from wh	ich a copy of	the oath or declaration is supplied under ecompanying application and is hereby
6.		Con	nputer Program in Mi	icrofiche (Appendix)		
7.	×	Nuc	cleotide and/or Amino	Acid Sequence Su	ıbmission	(if applicable,	all must be included)
	a.	X	Paper Copy				
	b.	×	Computer Readable	e Copy (identical to	computer	сору)	
	c.	X	Statement Verifying	Identical Paper and	d Comput	er Readable (Сору
				Accompanyi	ng Applic	ation Parts	
8.		Ass	ignment Papers (cov	er sheet & docume	nt(s))		
9.		37 (CFR 3.73(B) Stateme	ent <i>(when there is a</i>	n assigne	e)	
10.		Eng	glish Translation Docu	ument <i>(if applicable</i>)		
11.		Info	ormation Disclosure S	Statement/PTO-144	9 🗆	Copies of IDS	S Citations
12.	X	Pre	liminary Amendment				
13.	X	Ack	knowledgment postca	urd			
14.	X	Cer	rtificate of Mailing				
		П	First Class 🛛 E	Express Mail <i>(Spec</i>	ifv Label I	Vo.): EV0527	66852US

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

4

	Accompanying Application Parts (Continued)
15.	Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	Additional Enclosures (please identify below):
	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
17.	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
	Warning
	An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

F€	e	Cal	cul	ation	and	Trai	nsmittal
----	---	-----	-----	-------	-----	------	----------

i ee calculation and transmittat									
CLAIMS AS FILED									
For #Filed #Allowed #Extra Rate					Rate	Fee			
Total Claims	52	- 20 =	32	х	\$18.00	\$576.00			
Indep. Claims	3	- 3 =	0	x	\$84.00	\$0.00			
Multiple Dependent Cla	aims (check if	applicable)	×			\$280.00			
	BASIC FEE \$740.00								
OTHER FEE (specify	purpose)					\$0.00			
TOTAL FILING FEE \$1,596.00									
The Commissioner as described below Charge the Credit any Charge any Charge the pursuant to	eck in the amount of \$1,596.00 to cover the filing fee is enclosed. Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP escribed below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Credit any overpayment. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.								

	MAILING BY "EXPRESS N Hauber, et al.	MAIL" (37 CFR 1.10)	Docket No. 15120
Serial No. Unassigned	Group Art Unit Unassigned		
ovention: COMPOUN COMPRISE	DS THAT AFFECT CD83 EXPRING SAID COMPOUNDS AND MI	ESSION, PHARMACEUTICAL ETHODS FOR IDENTIFYING	COMPOSITIONS SAID COMPOUNDS
I hereby certify that the New Patent Application	e following correspondence:		
L	, , ,	of correspondence)	
		·	
		Janet Gross	
	40	(Typed or Printed Name of Person M (Signature of Person Mailing	Correspondence)
		EV05276685 ("Express Mail" Mailing	

Note: Each paper must have its own certificate of mailing.

Unassigned

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Joachim Hauber, et al. Examiner:

Serial No.: Unassigned Art Unit: Unassigned

Filing Date: Herewith Docket: 15120

For: COMPOUNDS THAT AFFECT CD83 Date: December 19, 2001

EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS

Assistant Commissioner for Patents Washington, DC 20231

VERIFICATION

Sir:

I hereby state that the content of the substitute paper and the substitute computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

L'eopoid Présser Registration No. 19.

SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530 (516) 742-4343 PIB:bg

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" mailing label number: EV052766852US

Date of Deposit: December 19, 2001

I hereby certify that this New Patent Application and Fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Dated: December 19, 2001

Ignet Grossman